Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Return on Sales (2021 - 2025)

Historic Return on Sales for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to 1.03%.

  • Rhythm Pharmaceuticals' Return on Sales rose 2800.0% to 1.03% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.1%, marking a year-over-year increase of 12000.0%. This contributed to the annual value of 2.0% for FY2024, which is 3800.0% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Return on Sales stood at 1.03% for Q3 2025, which was up 2800.0% from 0.96% recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Return on Sales ranged from a high of 1250.0% in Q1 2021 and a low of 129.16% during Q2 2021
  • Moreover, its 5-year median value for Return on Sales was 2.43% (2023), whereas its average is 51.64%.
  • The largest annual percentage gain for Rhythm Pharmaceuticals' Return on Sales in the last 5 years was 1242100bps (2022), contrasted with its biggest fall of -12850700bps (2022).
  • Over the past 5 years, Rhythm Pharmaceuticals' Return on Sales (Quarter) stood at 27.99% in 2021, then skyrocketed by 83bps to 4.83% in 2022, then soared by 64bps to 1.72% in 2023, then soared by 40bps to 1.03% in 2024, then grew by 0bps to 1.03% in 2025.
  • Its Return on Sales stands at 1.03% for Q3 2025, versus 0.96% for Q2 2025 and 1.51% for Q1 2025.